oditrasertib (DNL788) / Sanofi, Denali Therap  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oditrasertib (DNL788) / Denali Therap, Sanofi
2021-004156-42: Phase 2 study for SAR443820 in participants with amyotrophic lateral sclerosis (ALS)

Ongoing
2
261
Europe
SAR443820, Film-coated tablet
Sanofi-aventis recherche & développement, Sanofi-Aventis recherche & développement
Amyotrophic lateral sclerosis, Amyotrophic lateral sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
2022-000049-34: Phase 2 study of SAR443820 in participants with multiple sclerosis (MS)

Ongoing
2
280
Europe
SAR443820, Film-coated tablet
Sanofi-aventis recherche & développement, Sanofi-Aventis recherche & développement
Multiple sclerosis Esclerosis Múltiple, Multiple sclerosis Esclerosis Múltiple, Diseases [C] - Nervous System Diseases [C10]
 
 
HIMALAYA, NCT05237284 / 2021-004156-42: Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Terminated
2
305
Europe, Canada, Japan, US, RoW
SAR443820, Placebo
Sanofi, Sanofi-Aventis recherche & développement
Amyotrophic Lateral Sclerosis
03/24
03/24
NCT05630547: A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis

Active, not recruiting
2
174
Europe, Canada, RoW
SAR443820, Placebo
Sanofi
Multiple Sclerosis
09/25
09/25

Download Options